Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- FDA Accepts sNDA for Aptiom to Treat Partial-Onset Seizures
January 9, 2015
- Takeda Begins PII/III, PIII Studies of Rasagiline
January 9, 2015
- Kyowa Kirin Licenses Anticancer Drug from Syndax in Japan and South Korea
January 9, 2015
- Leading Generic Makers Disclose FY2013 Payments to Healthcare Professionals
January 8, 2015
- Celgene Applies for Additional Indication of Untreated Multiple Myeloma for Revlimid
January 8, 2015
- Hospira’s Oxaliplatin Generics Approved for Unresectable Pancreatic Cancer
January 8, 2015
- Takeda’s Potassium-Competitive Acid Blocker Approved in Japan
January 7, 2015
- Perampanel Meets Primary Endpoint in PIII Study for Asian Patients: Eisai
January 7, 2015
- Janssen Obtains Approval of Anti-HIV Drug Prezista Tablets 600 mg
January 7, 2015
- Taiho Obtains Approval of Double-Bag Formulation of Zosyn
January 7, 2015
- NBI Receives Approval for SGLT-2 Inhibitor Jardiance
January 6, 2015
- Takeda to Terminate License Agreement with AMAG for Iron Deficiency Anemia Treatment Ferumoxytol
January 6, 2015
- Sumitomo Dainippon to Reorganize Production Bases to Create Efficient, Low-Cost Production System
January 6, 2015
- AnGes MG Changes Development Strategy for NF-κB Decoy Oligo
January 5, 2015
- Shin Nippon Biomedical Laboratories to Tie Up with US CRO for Clinical Development Services
January 5, 2015
- Opdivo Receives Accelerated Approval in US for Malignant Melanoma: BMS
January 5, 2015
- Bayer Yakuhin Files PAH Drug Iloprost for Approval
December 26, 2014
- Sumitomo Dainippon Aims to File Lurasidone in Japan in FY2015 following Favorable Asian PIII Study Results
December 26, 2014
- Chugai Wins First Round in Patent Infringement Lawsuit for Oxarol Ointment
December 26, 2014
- Otsuka Obtains Rights from ARIAD to Develop, Commercialize Ponatinib in Japan and Other Asian Countries
December 26, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…